InvestorsHub Logo
Followers 2
Posts 309
Boards Moderated 0
Alias Born 02/26/2019

Re: None

Thursday, 07/18/2019 8:10:25 PM

Thursday, July 18, 2019 8:10:25 PM

Post# of 430205
Trying to put this secondary offering in context.

JT raised the revenue forecast. Announced it to the world. "Amarin management anticipates higher sales revenues." What else can be interpreted from that? They aren't absolutely certain of higher sales, but they aren't anticipating lower sales. Just expecting higher sales and hoping for higher sales.

And in anticipation, they are hiring more sales reps. Perhaps there is also a need to create marketing materials including print and television ads, ramp up drug production, and have money for unanticipated needs.

And so, they want the money now, a little over two months before an anticipated FDA approval.

But of course money doesn't grow on trees, and JT is not a magician.

Hence the secondary offering.

Not saying this didn't hurt me. It hurt a lot. I hate this. I was expecting $23 a share about now. But somebody has to pay up if we want to take full advantage of what looks like a promising situation.

No doubt, I'm frustrated too. I wish this were a lot easier, like investing in Amazon. Just hoping and praying it pans out.

But in context, I think we still have a good thing going.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News